(Q44164380)

30 November 2017

title

Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis (English)

1 reference

30 November 2017

Syed M Faisal

1

1 reference

30 November 2017

WeiWei Yan

2

1 reference

30 November 2017

Sean P McDonough

3

1 reference

30 November 2017

Hussni O Mohammed

4

1 reference

30 November 2017

Thomas J Divers

5

1 reference

30 November 2017

Yung-Fu Chang

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

26 August 2009

1 reference

30 November 2017

1 reference

30 November 2017

volume

27

1 reference

30 November 2017

issue

44

1 reference

30 November 2017

page(s)

6129-6136

1 reference

Leptospirosis, water sports, and chemoprophylaxis

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Reemerging leptospirosis, California

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Outbreak of Leptospirosis among Triathlon Participants and Community Residents in Springfield, Illinois, 1998

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospirosis in the tropics and in travelers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospirosis: a zoonotic disease of global importance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Evidence of cross-protection within Leptospira interrogans in an experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Activation of bovine peripheral blood gammadelta T cells for cell division and IFN-gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospira interrogans activation of human peripheral blood mononuclear cells: preferential expansion of TCR gamma delta+ T cells vs TCR alpha beta+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gammadelta T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Evaluation of type 1 immune response in naïve and vaccinated animals following challenge with Leptospira borgpetersenii serovar Hardjo: involvement of WC1(+) gammadelta and CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Recombinant subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Immunogenicity of the recombinant leptospiral putative outer membrane proteins as vaccine candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Leptospiral immunoglobulin-like proteins elicit protective immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Adjuvants--a balance between toxicity and adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Preparation of liposomes containing factor VIII for oral treatment of haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Controlled release microparticles for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Immunological adjuvants: a role for liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Gregory Gregoriadis: Introducing liposomes to drug delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Epaxal: a virosomal vaccine to prevent hepatitis A infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.029

10.1016/J.VACCINE.2009.08.029

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference